TheraCryf plc (LSE:TCF) has reported meaningful progress on Ox-1, its lead programme targeting addiction, which remains on schedule for regulatory submission by the end of 2026. The company has selected Pharmaron as its development partner and is expanding manufacturing capabilities to satisfy regulatory readiness. TheraCryf posted a post-tax loss of £1.3 million, but confirmed that its cash resources are sufficient to fund operations through late 2026. With the addiction-treatment market estimated at more than $40 billion, the company sees a sizeable commercial opportunity as it works to address both the societal and economic toll of addiction through its emerging therapy.
The broader outlook highlights continuing financial and operational hurdles, including ongoing losses and revenue pressure. Technical indicators present a mixed picture, though recent strategic steps offer a more constructive view, particularly as the company advances priority development programmes and focuses on strengthening its financial footing.
More about TheraCryf plc
TheraCryf plc is a clinical-stage biotech company developing treatments for a range of brain-related disorders, including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental conditions. Its strategy centres on generating strong preclinical and clinical proof-of-concept data and partnering with mid-sized and major pharmaceutical companies for later-stage trials and commercialisation. The company works closely with leading universities and hospitals and is based in Alderley Park, Cheshire.
Leave a Reply